Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 41Myeloproliferative Disorders 30Polycythemia Vera 28Myelodysplastic Syndromes 15Leukemia, Myeloid, Acute 13Thrombocythemia, Essential 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms 7Myelodysplastic-Myeloproliferative Diseases 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Hematologic Diseases 5Thrombocytosis 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Bone Marrow Diseases 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Graft vs Host Disease 2Breast Neoplasms 2Blast Crisis 2Anemia 2

Interventions

Imatinib Mesylate 5venetoclax 1ruxolitinib 1pevonedistat 1nilotinib 1Watchful Waiting 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × ruxolitinib × Myeloid × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡